APRIL

Aurinia Submits IND Application to US Food & Drug Administration for AUR 200

Retrieved on: 
Wednesday, December 20, 2023
Research, FDA, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Research and development, Food, Immunoglobulin A, Autoimmune disease, BAFF, IND, IgA nephropathy, APRIL, Lupus, Mouse, BCMA, Investigational New Drug, Membrane protein, B-cell activating factor, Rheumatology, American College, Safety, B cell, Pharmaceutical industry

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) – Aurinia announced today the submission of its Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) for AUR200, a potential next generation therapy for B-cell mediated autoimmune diseases.

Key Points: 
  • Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) – Aurinia announced today the submission of its Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) for AUR200, a potential next generation therapy for B-cell mediated autoimmune diseases.
  • AUR200 is a highly potent and specific Fc-fusion protein containing a modified B cell maturation antigen (BCMA), for enhanced binding to both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand).
  • “Our IND submission for AUR200 is an important step forward for Aurinia’s pipeline and our mission to change the trajectory of autoimmune disease.
  • Aurinia acquired AUR200 as part of a strategy to diversify its development pipeline and leverage existing R&D capabilities to advance innovative therapeutic solutions to help people living with autoimmune diseases.

Alpine Immune Sciences Presents New Translational Data on Povetacicept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023

Retrieved on: 
Wednesday, November 15, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, APRIL, Rheumatology, WT, Patient, TACI, Inflammation, Lupus, American College, Glomerulonephritis, BAFF, SLE, ALPN, Immunoglobulin A, Trial of the century, BCMA, Autoimmunity, IgA nephropathy, Pharmaceutical industry, Vaccine

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced today that the Company presented new translational data for povetacicept (ALPN-303) in systemic lupus erythematosus (SLE) at the American College of Rheumatology Convergence 2023, November 10-15, 2023.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced today that the Company presented new translational data for povetacicept (ALPN-303) in systemic lupus erythematosus (SLE) at the American College of Rheumatology Convergence 2023, November 10-15, 2023.
  • In SLE patients, BAFF- and APRIL-related genes (i.e., BAFF, APRIL, TACI, and BCMA) are increased in myeloid lineage cells and B cells compared to healthy adults.
  • Povetacicept, as compared to single BAFF or APRIL pathway inhibitors, more potently downregulates genes associated with activation in B cells.
  • Povetacicept significantly reduces multiple disease parameters in a mouse model of lupus, more effectively than WT TACI-Fc or conventional B cell depletion.

Alpine Immune Sciences Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 14, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Immunoglobulin G, ASN, PMN, UPCR, Investment, Clinical trial, American Society of Nephrology, APRIL, Glomerular filtration rate, Administration, Patient, TACI, Inflammation, Immunoglobulin A, Neonatal Fc receptor, Lupus, Infection, Research program, BAFF, SLE, ALPN, Immunoglobulin M, MD, Development, EGFR, BCMA, Society, NIH Intramural Research Program, Autoimmunity, Proteinuria, AANEM, Pharmaceutical industry, Sewage treatment, Vaccine, Paint, IgA nephropathy, AbbVie, Alpine

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results and company highlights for the third quarter ended September 30, 2023.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results and company highlights for the third quarter ended September 30, 2023.
  • “Following our data presentation, we executed a follow-on equity offering of $150 million to bolster our balance sheet.
  • Cash Position and Runway: As of September 30, 2023, Alpine’s cash and investments totaled $227.2 million compared to $273.4 million as of December 31, 2022.
  • The respective increases of $0.8 million and $2.3 million were primarily attributable to increases in personnel and legal costs.

Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results

Retrieved on: 
Thursday, November 9, 2023
APRIL, Hematuria, EGFR, Quarter, Society, American Society of Nephrology, BAFF, Disease, Risk, Serum, Kidney disease, Kidney, Vera, Therapy, Patient, Death, Immunoglobulin A, Proteinuria, Pharmaceutical industry, Cryptocurrency, IgA nephropathy

“Vera presented additional positive data from the Phase 2b ORIGIN trial at Kidney Week 2023, which support the potential of atacicept as a disease-modifying treatment for patients with IgAN.

Key Points: 
  • “Vera presented additional positive data from the Phase 2b ORIGIN trial at Kidney Week 2023, which support the potential of atacicept as a disease-modifying treatment for patients with IgAN.
  • We showed that patients on atacicept achieved durable and significant Gd-IgA1 reduction over 36 weeks regardless of baseline quartile.
  • High serum levels of galactose-deficient IgA1 (Gd-IgA1) are associated with greater risk of end-stage renal disease or death.
  • Vera reported $159.9 million in cash, cash equivalents, and marketable securities as of September 30, 2023.

Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023

Retrieved on: 
Saturday, November 4, 2023
Patient, APRIL, Hematuria, EGFR, Tetanus, Diphtheria, Immunoglobulin A, Poster, Society, American Society of Nephrology, BAFF, Disease, COVID-19, Risk, Immunity, ASN, Kidney disease, Safety, Overalls, UPCR, Therapy, Kidney, Death, Infection, Proteinuria, Mineral wool, Pharmaceutical industry, Vaccine, IgA nephropathy

BRISBANE, Calif., Nov. 04, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the presentation of three posters – including an additional analysis of week 36 data from the Phase 2b ORIGIN study demonstrating resolution of hematuria in the majority of patients – on the Company’s product candidate atacicept in patients with immunoglobulin A nephropathy (IgAN) at the American Society of Nephrology (ASN) Kidney Week 2023, in Philadelphia, PA.

Key Points: 
  • Analysis of week 36 data from Phase 2b ORIGIN study shows atacicept 150 mg substantially reduces serum Gd-IgA1 and resolves hematuria in the majority of patients.
  • Additional poster presentations provide further safety analysis of Phase 2b and details of pivotal Phase 3 clinical trial design, which is currently enrolling.
  • At week 36 of the ORIGIN Phase 2b study of atacicept in patients with IgAN, hematuria resolved in 80% of patients (n=12/15) receiving atacicept 150 mg compared to 5% (n=1/19) in the placebo group.
  • Through the randomized, placebo-controlled period, infections were balanced between atacicept and placebo in both the Phase 2a JANUS and Phase 2b ORIGIN studies.

APRIL International strengthens its presence in Europe with the acquisition of Expat & Co in Belgium

Retrieved on: 
Thursday, October 19, 2023
April Group, Insurance, APRIL, Acquisition, University, Telehealth, Ecosystem, Student, Tourism, Pharmaceutical industry, IPMI

LYON, France and PARIS, Oct. 19, 2023 /PRNewswire/ -- Expat & Co is the leading independent underwriter of insurance for expatriates in Belgium and offers a platform of solutions to support its customers made up of universities, individuals and companies, including multinationals based in several European countries.

Key Points: 
  • APRIL Group, Europe's leading wholesale insurance broker, announces the acquisition of Expat & Co, a specialist in international health insurance in Belgium.
  • Through this acquisition, APRIL International strengthens its presence on the European continent in a high-potential market for expatriation and international mobility and enhances its portfolio of solutions and health products.
  • Expat & Co will also draw on APRIL's technological and service base to simplify its customers' international healthcare experience.
  • Expat & Co is thus moving from the start-up phase to the scale-up phase in a single step".

APRIL International strengthens its presence in Europe with the acquisition of Expat & Co in Belgium

Retrieved on: 
Thursday, October 19, 2023
April Group, Insurance, APRIL, Acquisition, University, Telehealth, Ecosystem, Student, Tourism, Pharmaceutical industry, IPMI

LYON, France and PARIS, Oct. 19, 2023 /PRNewswire/ -- Expat & Co is the leading independent underwriter of insurance for expatriates in Belgium and offers a platform of solutions to support its customers made up of universities, individuals and companies, including multinationals based in several European countries.

Key Points: 
  • APRIL Group, Europe's leading wholesale insurance broker, announces the acquisition of Expat & Co, a specialist in international health insurance in Belgium.
  • Through this acquisition, APRIL International strengthens its presence on the European continent in a high-potential market for expatriation and international mobility and enhances its portfolio of solutions and health products.
  • Expat & Co will also draw on APRIL's technological and service base to simplify its customers' international healthcare experience.
  • Expat & Co is thus moving from the start-up phase to the scale-up phase in a single step".

Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Thursday, March 23, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Emory University School of Medicine, APRIL, Cold agglutinin disease, Dermatology, Kidney, American Academy, Immunoglobulin A, Lupus, Publication, Investment, Dialysis, Transplant, IgA nephropathy, Hospital, Medical director, MD, AbbVie, ALPN, Patient, Lupus nephritis, Webcast, BAFF, Cytokine, Horizon, Autoimmunity, Inflammation, Glomerulonephritis, Pharmaceutical industry, Gemstone, Nursing, Cryptocurrency, Alpine, Medicine

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for the fourth quarter ended December 31, 2022.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for the fourth quarter ended December 31, 2022.
  • Collaboration revenue for the quarter ended December 31, 2022 was $2.8 million compared to $4.5 million for the quarter ended December 31, 2021.
  • Research and development expenses for the quarter ended December 31, 2022 were $18.8 million compared to $15.4 million for the quarter ended December 31, 2021.
  • The Company recorded net losses of $18.9 million and $15.2 million for the quarters ended December 31, 2022 and 2021, respectively.

Accelerating its international development, the APRIL Group establishes an entity in Germany

Retrieved on: 
Thursday, November 17, 2022
Growth, April Group, Health, Length of stay, Social responsibility, Oxygen, VSE Corporation, Insurance, Cologne, APRIL, Financial services

LYON, France and PARIS, Nov. 17, 2022 /PRNewswire/ --The APRIL Group, France's leading wholesale insurance broker, is enjoying strong growth across multiple markets and now accelerating its international development by setting up APRIL International GmbH.

Key Points: 
  • LYON, France and PARIS, Nov. 17, 2022 /PRNewswire/ --The APRIL Group, France's leading wholesale insurance broker, is enjoying strong growth across multiple markets and now accelerating its international development by setting up APRIL International GmbH.
  • This new entity will help APRIL provide even closer support to its expatriate German policyholders and the insurance brokers that advise them.
  • Opening our German subsidiary is the first step of this push,"explains Isabelle Moins, CEO of APRIL International in Europe.
  • "Setting up this entity in Germany, in one of the continent's most dynamic markets, is a further step that underscores our goal of becoming an international leaderin wholesale insurance.

RemeGen Biosciences to Present New Data Updates in ACR 2022

Retrieved on: 
Friday, November 11, 2022
ACR, Immunoglobulin G, Multimedia, Control, Ageing, Systematic, BAFF-R, Rheumatoid arthritis, B cell, Survival, Fast track (FDA), BCMA, IgA nephropathy, PPS, National Medical Products Administration, Șaeș, III, Urinary tract infection, Immunoglobulin M, Adult, Research, Autoimmunity, American College of Rheumatology, Patient, SAN, NRDL, Lymphocyte, B-cell activating factor, CAML, ANA, Safety, SLE, American College, NMPA, Mab, Antibody, TACI, Sjögren syndrome, Population, AES, PSS, APRIL, Upper respiratory tract infection, Immunoglobulin A, Week, Pharmaceutical industry, Online shopping

This event will present Telitacicept phase III clinical trial data on Systematic lupus erythematosus (SLE) and data from the phase II clinical trial for Sjorgren's syndrome.

Key Points: 
  • This event will present Telitacicept phase III clinical trial data on Systematic lupus erythematosus (SLE) and data from the phase II clinical trial for Sjorgren's syndrome.
  • Telitacicept for Systematic Lupus Erythematosus, data from phase III trial
    This is a 52-week, randomized, double-blind, placebo-controlled, phase III clinical trial (NCT04082416).
  • RemeGen, Ltd. ("RemeGen") is a leading biopharmaceutical company in China dedicated to fulfilling unmet medical needs for patients with life-threatening conditions.
  • Since its inception in 2008, RemeGen has created more than 10 novel drug molecules in various clinical development stages.